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Neisseria elongata (NE) is an aerobic Gram-negative organism that constitutes part of the commensal human normal oropharyngeal
flora. Although previously considered not to be pathogenic, it has been recognized as an occasional cause of significant infections
in humans.We report here the first case in Italy of infective endocarditis of a native prolapsing mitral valve in a patient withMarfan
syndrome, caused by NE subspecies nitroreducenswhich has been rarely isolated from clinical specimens.The culprit organism has
been confirmed bymass spectrometry directly from the positive blood culture, as previously reported.The amplified gene has been
deposited in GenBank under accession number KT591873. In spite of the reported aggressive nature of NE, clinical remission was
promptly obtained, there being no requirement for surgery.
1. Introduction
Neisseria elongata (NE) is an aerobic Gram-negative organ-
ism that constitutes part of the commensal human normal
oropharyngeal flora [1]. Several biochemical characteristics
can be used to differentiate the organism into three sub-
species: elongata, glycolytica, and nitroreducens. Although
previously considered not to be pathogenic, it has been
recognized as an occasional cause of significant infections
in humans, such as infective endocarditis (IE), septicaemia,
and osteomyelitis. The subspecies nitroreducens is the most
frequently involved [1–4].We report here the first case in Italy
of IE of a native prolapsing mitral valve caused by NE subsp.
nitroreducens in a patient with Marfan syndrome.
2. Case Report
A 40-year-old ItalianmanwithMarfan syndromewas admit-
ted to our hospital because of remittent fever reaching up
to 39, lasting for one week. Therapy with oral amoxicillin-
clavulanic acid, prescribed by his general physician six days
earlier, was ineffective in improving his symptoms. He denied
any recent dental procedures or odontogenic infections, nor
invasive procedures.
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Figure 1: TTE 4-chamber views showing (a) a vegetation arising from the posterior leaflet of mitral valve.The vegetation was confirmed with
TOE (c) that also documented a severe mitral regurgitation (d) and the prosthetic aortic valve (b). la: left atrium, lv: left ventricle, ra: right
atrium, rv: right ventricle, and AoP: prosthetic aortic valve.
In 1992, at the age of 17, he underwent composite aortic
valve and root replacement with a composite graft that
consisted of Starr Edward’s aortic prosthesis and a suitably
sized Dacron tube. A routine transthoracic echocardiogram
(TTE) performed one year before hospital admission showed
mitral valve prolapse with severe mitral regurgitation.
On admission the following parameters were detected:
arterial blood pressure of 120/60mmHg, heart rate of 117 bpm
(regular rhythm), body temperature of 38∘C, and arterial
oxygen saturation of 97%.The physical examination revealed
a systolic murmur at the left sternal border. Neither muco-
cutaneous signs related to infective endocarditis, such as
Janeway lesions, splinter haemorrhages, Osler nodes, and
conjunctival petechiae, nor active intraoral lesions were
detected; the neurological examination was unremarkable.
Blood test demonstrated normal white blood cell count
but elevated levels of C-reactive protein (>75mg/L).The elec-
trocardiogram showed sinus tachycardia and left ventricular
hypertrophy. Transthoracic and transesophageal echocar-
diography (TOE) showed left atrium enlargement and left
ventricular hypertrophy with normal LV ejection fraction; it
also revealed the presence of a vegetation on the posterior
leaflet of mitral valve (12mm in diameter) (Figure 1) and
confirmed the severity of mitral regurgitation. The patient
underwent a computed tomography (chest, abdomen, and
brain) that excluded signs of infection or haematogenous dis-
semination. As suggested by the current European guidelines,
an empirical antimicrobial therapy for native valve endo-
carditis was started with intravenous amoxicillin/clavulanic
acid (875mg/125mg × 3 die) and gentamicin (80mg × 2
die). On hospital day 3 the patient became apyretic and
he remained so throughout the entire clinical course; C-
reactive protein progressively declined. After seven days, the
admission blood cultures grew Gram-negative coccobacilli,
susceptible to a broad spectrum of antibiotics, including
gentamicin and ceftazidime. Furthermore, through a molec-
ular approach based on 16 S ribosomal DNA sequencing,
the isolate was identified to be N. elongata. The patient
was switched from amoxicillin to intravenous ceftazidime
(2 g × 3 die) in addition to gentamicin. After two weeks of
appropriate treatment C-reactive protein returned to normal.
After 18 days the blood cultures obtained during the patient’s
antibiotic therapy were negative. However, despite clinical
and laboratory remission, TOE performed on day 19 detected
two little vegetations (maximum diameter 6mm) on the
mitral valve (Figure 2). The patient was discharged on day
21, in good clinical condition with the recommendation to
continue the antibiotic therapy (intramuscular gentamicin
and intramuscular ceftazidime) for other three weeks. A
follow-up TTE performed onemonth after hospital discharge
showed the complete resolution of the vegetation.
3. Discussion
We report here the first case in Italy of infective endocarditis
caused by NE subsp. nitroreducens, which has been rarely
isolated from clinical specimens. To the best of our knowl-
edge, more than 20 cases of NE endocarditis have appeared







Figure 2: TOE 4 chambers: the admission of TOE on (a) shows a vegetation on the posterior leaflet of mitral valve. The follow-up TOE (b)
confirmed the persisting of the vegetation of reduced dimensions, compared with the previous exam (a), despite clinical remission.
in the literature, of which 18, including the present case,
fulfilled themodifiedDukes criteria for a definite diagnosis of
infective endocarditis [5]. Preexisting heart diseases (valvular
or congenital heart disease) are considered as risk factors for
N. elongata endocarditis [6–8]. However, some cases have
also been occasionally reported in patients without previous
apparent cardiac disease [9].
Neisseria-induced endocarditis seems to have a poor
prognosis and the disease course might be complicated and
potentially fatal. A review of definitive or possible cases of N.
elongata endocarditis showed that approximately half of the
patients underwent surgical treatment [10].Moreover, it often
results in severe cardiac and systemic complications such as
systemic embolization, heart failure, and myocardial abscess
[11, 12]. Thus, its involvement in an infective process should
be promptly treated and managed with close follow-up.
Some authors have suggested that clinicians should consider
extended antibiotic treatment and early surgical evaluation
[13]. To date, the drug susceptibility testing of NE has not
yet been standardized. However, this organism is generally
considered to be susceptible to awide range of antibiotics [14].
Many cases of endocarditis are treated with beta-lactams,
often in combination with aminoglycosides, for four to six
weeks [10]. However, appropriate protocols for antibacterial
treatment should be established with further cases.
In conclusion, to the best of our knowledge, we present
the first case in Italy of definite diagnosis of IE caused by NE
subspecies nitroreducens. The patient underwent a previous
replacement of aortic valve, but the infection involved the
native prolapsing mitral valve. No recent invasive procedures
or oral manipulation was reported as major risk factors. The
last time the patient went to the dentist was several years
before the hospital admission. Hence, we speculate that NE
entered the bloodstream during unrecognized oral events,
such as daily dental care. Cases originating from a skin
infection have also been reported [15]. The culprit organism
has been confirmed by mass spectrometry directly from the
positive blood culture, as previously reported. The amplified
production including 1416 nucleotides of the 16SrRNA gene
of NE subsp. nitroreducens was deposited in GenBank under
accession number KT591873, as previously described [16].
The rapid identification has enabled us to administer a correct
chemical therapy. In spite of the reported aggressive nature
of NE, clinical remission was promptly obtained with intra-
venous ceftazidime in addition to gentamicin, there being no
requirement for surgery during the acute phase of the disease.
No local or systemic complication was reported.
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